Back to Alzheimers Disease
NCT00829816
NCT00829816
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with Alzheimer's disease
- You are currently taking a medication called Memantine
- You have a caregiver who is willing to come with you to all of your clinic appointments
Who may not be able to join:
- You have unstable health conditions, or serious liver or kidney disease
- You have another main psychiatric (mental health) or neurological (brain or nervous system) condition besides Alzheimer's
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 1
Sponsor
Medivation, Inc.
Registry
clinicaltrials_gov
Start date
1 December 2008
Est. completion
1 April 2009
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
To assess the safety and tolerability of orally administered dimebon in patients with Alzheimer's disease (AD) on a stable dose and regimen of memantine, or memantine plus donepezil.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.